High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 17, 2010, Pages 7904-7909

  Zhoua, Yiming ^a   Chena, Lijuan ^a,b   Barlogiea, Bart ^a   Stephensa, Owen ^a   Wua, Xiaosong ^a   Williamsa, David R ^a   Van Rheea, Frits ^a   Naira, Bijay ^a   Waheeda, Sarah ^a   Pineda Romana, Mauricio ^a   Alsayeda, Yazan ^a   Anaissiea, Elias ^a   Shaughnessy Jr , John D ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARGONAUTE 2 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1A; MICRORNA; SYNDECAN 1;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RISK; CLINICAL FEATURE; GENE CONTROL; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MYELOMA; PLASMA CELL; PRIORITY JOURNAL; UPREGULATION;

APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; CLUSTER ANALYSIS; EUKARYOTIC INITIATION FACTOR-2; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; MULTIPLE MYELOMA; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OLIGONUCLEOTIDES; RISK ASSESSMENT; SYNDECAN-1;

EID: 77952340609     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0908441107     Document Type: Article

References (39)

1. Bartel DP (2004) MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116:281-297.
2. Fabbri M, Croce CM, Calin GA (2009) MicroRNAs in the ontogeny of leukemias and lymphomas. Leuk Lymphoma 50:160-170.
3. Visone R, Croce CM (2009) MiRNAs and cancer. Am J Pathol 174:1131-1138.
4. Bartels CL, Tsongalis GJ (2009) MicroRNAs: Novel biomarkers for human cancer. Clin Chem 55:623-631.
5. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev Cancer 6: 857-866.
6. Iorio MV, Casalini P, Tagliabue E, Ménard S, Croce CM (2008) MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. Eur J Cancer 44:2753-2759.
7. Krützfeldt J, et al. (2005) Silencing of microRNAs in vivo with 'antagomirs'. Nature 438:685-689.
8. Czech MP (2006) MicroRNAs as therapeutic targets. N Engl J Med 354:1194-1195.
9. Medina PP, Slack FJ (2009) InhibitingmicroRNA function in vivo. Nat Methods 6:37-38.
10. Barlogie B, Shaughnessy J, Epstein J, Sanderson R, Anaissie E, Walker R, Tricot G (2005) Williams Hematology, eds Marshall AL, Beutler E, Kaushansky K, Kipps TJ, Seligsohn U, Prchal J (McGraw-Hill, New York), pp 1501-1533.
11. Löffler D, et al. (2007) Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood 110:1330-1333. (Pubitemid 47281433)
12. Pichiorri F, et al. (2008) MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci USA 105:12885-12890.
13. Roccaro AM, et al. (2009) MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood 113:6669-6680.
14. Lionetti M, et al. (2009) Integrative high-resolution microarray analysis of human myeloma cell lines reveals deregulated miRNA expression associated with allelic imbalances and gene expression profiles. Genes Chromosomes Cancer 48:521-531.
15. Nicoloso MS, Kipps TJ, Croce CM, Calin GA (2007) MicroRNAs in the pathogeny of chronic lymphocytic leukaemia. Br J Haematol 139:709-716. (Pubitemid 350115732)
16. Diederichs S, Haber DA (2007) Dual role for argonautes in microRNA processing and posttranscriptional regulation of microRNA expression. Cell 131:1097-1108. (Pubitemid 350235019)
17. Liu J, et al. (2004) Argonaute2 is the catalytic engine of mammalian RNAi. Science 305: 1437-1441. (Pubitemid 39167657)
18. O'Carroll D, et al. (2007) A Slicer-independent role for Argonaute 2 in hematopoiesis and the microRNA pathway. Genes Dev 21:1999-2004. (Pubitemid 47267286)
19. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ (2008) miRBase: Tools for microRNA genomics. Nucleic Acids Res 36 (Database issue):D154-D158.
20. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98:5116-5121. (Pubitemid 32397092)
21. Shaughnessy J, et al. (2000) High incidence of chromosome 13 deletion in multiple myeloma detected by multiprobe interphase FISH. Blood 96:1505-1511. (Pubitemid 30658483)
22. Tricot G, et al. (1995) Poor prognosis in multiple myeloma is associated only with partial or complete deletions of chromosome 13 or abnormalities involving 11q and not with other karyotype abnormalities. Blood 86:4250-4256.
23. Shaughnessy JD, Jr, et al. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 109:2276-2284.
24. Subramanian A, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102:15545-15550. (Pubitemid 41528093)
25. Rhodes DR, et al. (2004) Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 101:9309-9314.
26. Tarte K, Zhan F, De Vos J, Klein B, Shaughnessy J, Jr (2003) Gene expression profiling of plasma cells and plasmablasts: Toward a better understanding of the late stages of B-cell differentiation. Blood 102:592-600. (Pubitemid 36841980)
27. Ramalho-Santos M, Yoon S, Matsuzaki Y, Mulligan RC, Melton DA (2002) "Stemness": Transcriptional profiling of embryonic and adult stem cells. Science 298:597-600.
28. Zhan F, et al. (2006) The molecular classification of multiple myeloma. Blood 108: 2020-2028.
29. Sethupathy P, Corda B, Hatzigeorgiou AG (2006) TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA 12:192-197. (Pubitemid 43121923)
30. Chen YH, et al. (1999) Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Blood 94:251-259.
31. Lavelle D, Chen YH, Hankewych M, DeSimone J (2001) Histone deacetylase inhibitors increase p21(WAF1) and induce apoptosis of human myeloma cell lines independent of decreased IL-6 receptor expression. Am J Hematol 68:170-178. (Pubitemid 32983205)
32. Stewart JP, et al. (2004) Correlation of TACC3, FGFR3, MMSET and p21 expression with the t(4;14)(p16.3;q32) in multiple myeloma. Br J Haematol 126:72-76.
33. Zhou Y, et al. (2008) Integration of DNA copy number and gene expression alteration reveal novel insights into the molecular pathogenesis and prognosis of multiple myeloma. Blood (ASH Annual Meeting Abstracts) 12:250.
34. Jinek M, Doudna JA (2009) A three-dimensional view of the molecular machinery of RNA interference. Nature 457:405-412.
35. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT (2005) c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435:839-843.
36. Chang TC, et al. (2008) Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet 40:43-50.
37. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T (2007) Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 39:673-677. (Pubitemid 46676103)
38. Merritt WM, et al. (2008) Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med 359:2641-2650.
39. Tarte K, et al. (2002) Generation of polyclonal plasmablasts from peripheral blood B cells: A normal counterpart of malignant plasmablasts. Blood 100:1113-1122. (Pubitemid 34864260)